Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Reviewer: Charles Wood, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 4 de julio del 2004
Authors: Vernon K. Sondak, P.-Y. Liu, Ralph J. Tuthill, Raymond A. Kempf, Joseph M. Unger, Jeffrey A. Sosman, John A. Thompson, Geoffrey R. Weiss, Bruce G. Redman, James G. Jakowatz, R. Dirk Noyes, and Lawrence E. Flaherty
Source: Journal of Clinical Oncology, Vol 20, No 8 (April 15), 2002: pp 2058-2066
There is no standard adjuvant therapy for completely resected, intermediate thickness, node-negative melanoma patients. Both external beam radiation treatment and cytotoxic chemotherapeutic agents have thus far demonstrated limited efficacy at best, prompting interest for novel adjuvant treatment modalities. Because of multiple case study reports of spontaneous regression of melanoma lesions, the disease was felt to be susceptible to attack by the immune system. To date, both autologous and allogeneic melanoma cancer vaccines have been used in the settings of either documented metastatic disease or in patients at high risk of harboring microscopic residual disease following resection. It stands to reason that vaccination might be more efficacious in the setting of minimal tumor burden due to issues of decreased tumor antigen heterogeneity and less tumor-induced immunosuppression. In 1990, the Southwest Oncology Group initiated development of a phase III clinical trial of allogeneic melanoma cell lysate for use as vaccine therapy in patients with completely resected, node negative melanoma. The vaccine chosen had shown an objective response rate in 7% of 81 patients in multicenter phase I and II trials in advanced melanoma, and was known to contain tumor antigens potentially able to induce a significant immune response.
Cancer vaccine therapy, while novel, is not a new treatment approach, as significant amounts of pre-clinical and phase I and II trials have been reported. However, the lack of encouraging phase III trials relegates the approach to one of experimental status with poor results to date. Though this trial was the largest of its kind, even larger patient populations will be required in the future should investigators wish to evaluate smaller but clinically significant differences. In addition, an allogeneic vaccine strategy, while much less expensive and time-consuming versus autologous preparations, has shown little activity in phase I and II trials, most probably due to the fact that the majority of effectively immunogenic tumor antigens are as of yet undiscovered. While an autologous vaccine approach seems to make better sense at the level of immune recognition and response, the cost and time implications involved render this largely impractical. Nevertheless, the field of vaccine therapy continues to garner much attention, and hope persists that significant advances will soon be reported.
Ms. Gambino talks about the complexity of cancer care and the need for patients and families to have help in navigating from diagnosis and treatment decisions to survivorship. Read more.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults